PARKERVISION (PRKR) 424B Filings

ParkerVision, Inc.'s Prospectus Supplement No. 52 updates a prospectus permitting selling shareholders to resell up to 16,638,353 shares of common stock issuable upon conversion of, and for payment of interest from time to time at the company's option for, convertible promissory notes dated between May 10, 2022 and August 3, 2022. The notes have a fixed conversion price of $0.13 per share. The supplement adds information from a current report dated October 29, 2026.

On October 23, 2026, ParkerVision's board expanded from four to five members and unanimously appointed William G. Walters to the resulting Class II director vacancy. Walters will receive the company's standard non-employee director compensation, and ParkerVision entered into its standard indemnification agreement with him.

ParkerVision, Inc.'s prospectus permits the selling stockholder to resell up to 1,578,946 shares of common stock. This comprises 1,052,631 common shares and 526,315 shares underlying Warrants. ParkerVision will receive no proceeds from the selling stockholder's sales; if Warrants are exercised for cash, it may receive up to $526,315 in gross proceeds, which it expects to use for general working capital, including litigation expenses.

On October 23, 2026, ParkerVision expanded its board from four to five members and unanimously appointed William G. Walters to fill the Class II director vacancy. Walters will receive the company's standard non-employee director compensation.

ParkerVision, Inc. (PRKR) permits selling stockholders to resell up to 13,342,953 shares of common stock. ParkerVision will not receive proceeds from those resales; if the warrants are exercised for cash, it could receive up to $2,833,756 in gross proceeds for general working capital, including litigation expenses.

The accompanying report states that on October 23, 2026, ParkerVision’s board expanded from four to five members and unanimously appointed William G. Walters to fill the resulting director vacancy. He will receive the company’s standard non-employee director compensation arrangements.

ParkerVision, Inc.'s prospectus permits selling stockholders to resell up to 5,871,584 shares of common stock. ParkerVision will not receive proceeds from those sales. On October 23, 2026, the board expanded from four to five members, creating a Class II director vacancy, and unanimously appointed William G. Walters to fill it. Walters, age 89, is retired from an investment banking career focused on micro and small cap companies and will receive the company's standard non-employee director compensation. ParkerVision entered into its standard indemnification agreement with him.

ParkerVision, Inc. (PRKR) updated its resale prospectus, which permits selling stockholders to resell up to 16,809,295 shares of common stock. The amount includes up to 4,961,538 shares issuable upon conversion of notes or for interest payments, 3,907,331 shares issued under securities purchase agreements, 2,740,426 shares issued for services and repayment of short-term loans and accounts payable, and up to 5,000,000 and 200,000 shares issuable upon warrant exercises at $0.74 and $1.00 per share, respectively.

ParkerVision receives no proceeds from selling-stockholder resales. Cash exercise of the warrants could provide up to $3,900,000 in gross proceeds for general working capital and corporate purposes. The update also reports that the board expanded from four to five members and appointed William G. Walters as a class II director; he will receive standard non-employee director compensation.

ParkerVision, Inc.’s prospectus permits selling stockholders to resell up to 18,014,164 shares of common stock. This includes up to 5,457,583 shares issuable upon conversion of Tranche 1 Notes at a fixed $0.10 per-share conversion price; up to 10,131,581 shares issuable upon conversion of Tranche 2 Notes at a fixed $0.08 per-share conversion price; 625,000 shares issued for consulting services; and up to 1,800,000 shares issuable upon exercise of a five-year warrant at $0.10 per share, subject to adjustment. ParkerVision receives no proceeds from stockholder resales; if the warrant is exercised for cash, it may receive up to $180,000 in gross proceeds for general working capital and corporate purposes. On October 23, 2026, the board expanded from four to five members and appointed William G. Walters as a class II director.

ParkerVision, Inc. (PRKR) states that its prospectus permits selling stockholders to resell up to 17,189,660 shares of common stock. ParkerVision receives no proceeds from those resales. If the 2016 Warrant is exercised for cash, the company will receive up to $700,000 in gross proceeds; it may receive up to an additional $1,763,500 from sales of its common stock or exercise of warrants issued to Aspire Capital. ParkerVision expects to use warrant-exercise proceeds, if any, for patent enforcement actions, working capital and general corporate purposes.

On October 23, 2026, the board expanded from four to five members and unanimously appointed William G. Walters to fill the resulting class II director vacancy. He will receive the company’s standard non-employee director compensation.

ParkerVision, Inc. (PRKR)'s prospectus permits the listed selling stockholders to resell up to 12,800,000 shares of Common Stock. The shares consist of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and, at the company's option, for interest payments, plus 5,000,000 shares issuable upon exercise of a five-year warrant. Selling stockholders receive proceeds from resales; ParkerVision may receive up to $800,000 in gross proceeds if the warrant is exercised for cash. The company expects to use any such proceeds for patent enforcement actions and other working capital and general corporate purposes.

On October 23, 2026, ParkerVision's board expanded from four to five members and unanimously appointed William G. Walters to fill a Class II director vacancy. He will receive the company's standard non-employee director compensation, and the company entered into its standard indemnification agreement with him.

ParkerVision, Inc. is updating a prospectus that permits selling shareholders to resell up to 9,387,500 shares of common stock.

The resale amount comprises 2,843,750 shares already issued under securities purchase agreements, 6,343,750 shares tied to conversion of convertible notes and interest payments at ParkerVision’s option, and 200,000 shares issuable upon exercise of options issued as payment for services. ParkerVision will not receive proceeds from selling shareholders’ resales. If the options are exercised for cash, ParkerVision could receive up to $42,620 in gross proceeds, which it expects to use for general working capital.

ParkerVision, Inc. (PRKR) has a prospectus permitting selling shareholders to resell up to 16,638,353 shares of common stock. The shares are issuable upon conversion of, and for payment of interest from time to time at ParkerVision’s option for, convertible promissory notes dated between May 10, 2022 and August 3, 2022; the notes have a fixed conversion price of $0.13 per share.

The supplement updates the existing prospectus with information from a current report. ParkerVision stated that the report announces the Federal Circuit issued an order in the expedited appeal of its patent infringement case against Qualcomm. ParkerVision also states that these Form 424B3 updates do not involve issuance of new securities.

ParkerVision, Inc. (PRKR) has a prospectus permitting the selling stockholder to resell up to 1,578,946 shares of common stock, comprising 1,052,631 shares of common stock and 526,315 shares underlying warrants. ParkerVision will not receive proceeds from resales. To the extent the warrants are exercised for cash, ParkerVision will receive up to $526,315 in gross proceeds, which it expects to use for general working capital, including litigation expenses.

ParkerVision also reported that the Court of Appeals for the Federal Circuit issued its order in the expedited appeal of the company’s patent infringement case against Qualcomm. The company stated that its Form 424B3 updates typically do not involve the issuance of new securities.

ParkerVision, Inc. updates its resale prospectus, which permits selling stockholders to resell up to 13,342,953 shares of common stock. The registered amount comprises 7,962,722 shares issued under securities purchase agreements, 3,230,942 shares issued under a March 29, 2021 agreement, 1,619,289 shares underlying warrants issued under that agreement, and 530,000 shares issued as payment for services.

ParkerVision will receive no proceeds from stockholder resales. If the warrants are exercised for cash, ParkerVision may receive up to $2,833,756 in gross proceeds and expects to use any proceeds received for general working capital, including payment of litigation expenses.

ParkerVision, Inc. (PRKR) is supplementing a resale prospectus that permits selling stockholders to resell up to 5,871,584 shares of common stock. The shares were issued under securities purchase agreements, and ParkerVision says it will receive no proceeds from the selling stockholders’ sales.

The attached 8-K reports that the Court of Appeals for the Federal Circuit issued an order in the expedited appeal of ParkerVision’s patent infringement case against Qualcomm. ParkerVision also says it will file Form 424B3 supplements to maintain the effectiveness of previously filed S-1 registration statements; it says those filings do not involve new securities issuance.

ParkerVision’s prospectus permits selling stockholders to resell up to 16,809,295 shares of common stock. The shares include up to 4,961,538 issuable upon conversion of convertible notes and for interest payments at ParkerVision’s option; 3,907,331 issued under securities purchase agreements; 2,740,426 issued for services and repayment of short-term loans and other payables; and warrant shares: up to 5,000,000 at $0.74 per share and up to 200,000 at $1.00 per share.

ParkerVision receives no proceeds from resales. Cash exercise of the Aspire and Tailwinds warrants could generate up to $3,900,000 in gross proceeds, which ParkerVision expects to use for general working capital and corporate purposes. Separately, ParkerVision disclosed that the Court of Appeals for the Federal Circuit issued an order on October 1, 2026, in the expedited appeal of its patent infringement case against Qualcomm.

ParkerVision, Inc. describes a resale by selling stockholders of up to 18,014,164 shares of its common stock. The shares include up to 5,457,583 shares issuable under the Tranche 1 Notes, up to 10,131,581 shares issuable under the Tranche 2 Notes, 625,000 shares issued for consulting services, and up to 1,800,000 shares issuable upon exercise of the Park Consulting Warrant. The notes have fixed conversion prices of $0.10 and $0.08 per share, respectively; the warrant has a $0.10 exercise price.

ParkerVision will not receive proceeds from selling stockholders’ resales. If the warrant is exercised for cash, ParkerVision could receive up to $180,000 in gross proceeds, expected to be used for general working capital and corporate purposes. ParkerVision also reported that the Court of Appeals for the Federal Circuit issued an order in the expedited appeal of its patent infringement case against Qualcomm.

ParkerVision, Inc. (PRKR) continues to permit selling stockholders to resell up to 17,189,660 shares of common stock under its April 19, 2019 prospectus. This supplement updates that prospectus with an October 1, 2026 Form 8-K; ParkerVision says its Form 424B3 updates maintain previously filed registration statements and do not involve issuance of new securities.

The resale amount includes 1,273,540 shares from a 2016 private placement and warrant, including up to 350,000 warrant shares at an exercise price of $2 per share; up to 10,000,000 shares issued or issuable to Aspire Capital under a 2018 agreement; and 5,916,120 shares issuable upon conversion of, or for interest on, 2018 notes with fixed conversion prices of $0.40 and $0.57 per share. ParkerVision says it receives no proceeds from selling-stockholder sales, but could receive up to $700,000 gross from cash exercise of the 2016 Warrant and may receive up to an additional $1,763,500 from common-stock sales or exercise of Aspire Capital warrants. The Form 8-K reports that the Federal Circuit issued an order in the expedited appeal of ParkerVision’s patent infringement case against Qualcomm.

ParkerVision, Inc. (PRKR) permits selling stockholders to resell up to 12,800,000 shares of common stock. The amount includes up to 7,800,000 shares issuable in connection with convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.

ParkerVision receives no proceeds from sales by selling stockholders. If the warrant is exercised for cash, ParkerVision may receive up to an aggregate of $800,000 in gross proceeds, which it expects to use for patent enforcement actions, working capital and general corporate purposes. The company also reported that the Court of Appeals for the Federal Circuit issued its order in the expedited appeal of its patent infringement case against Qualcomm.

PARKERVISION, INC. (PRKR)'s prospectus permits selling shareholders to resell up to 9,387,500 shares of common stock. The amount includes 2,843,750 shares issued under securities purchase agreements, 6,343,750 shares issuable upon conversion of Convertible Notes or, at the company's option, for interest, and 200,000 shares issuable upon exercise of service-payment options. The Convertible Notes have a fixed conversion price of $0.16 per share.

The company will not receive proceeds from selling-shareholder resales. If the Options are exercised for cash, it will receive up to an aggregate of $42,620 in gross proceeds, which it expects to use for general working capital. At the September 25, 2026 annual meeting, shareholders elected Jeffrey L. Parker as a Class I director and Anthony B. Bowers as a Class II director, and ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026.

ParkerVision, Inc.’s prospectus permits selling shareholders to resell up to 16,638,353 shares of common stock issuable upon conversion of convertible promissory notes and, at the company’s option, for interest payments. The notes have a fixed conversion price of $0.13 per share. This supplement updates the prospectus with the company’s annual meeting results.

At the September 25, 2026 annual meeting, shareholders elected Jeffrey L. Parker as a Class I director for a term expiring at the 2029 annual meeting and Anthony B. Bowers as a Class II director for the remaining term expiring at the 2027 annual meeting. Shareholders also ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026. The company had 148,226,874 common shares issued and outstanding and entitled to vote as of July 29, 2026.

ParkerVision, Inc. (PRKR) permits the selling stockholder to resell up to 1,578,946 shares of common stock, comprising 1,052,631 common shares and 526,315 shares underlying warrants. ParkerVision receives no proceeds from resales; if the warrants are exercised for cash, it could receive up to $526,315 in gross proceeds, expected for general working capital, including payment of litigation expenses.

At the September 25, 2026 annual meeting, shareholders elected Jeffrey L. Parker as a Class I director for a term expiring at the 2029 annual meeting and Anthony B. Bowers as a Class II director for the remaining term expiring at the 2027 annual meeting. Shareholders ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026. Parker and Bowers received 21,862,556 and 22,063,764 votes for election, respectively; the accounting firm received 93,703,944 votes for ratification.

ParkerVision, Inc. (PRKR) permits the selling stockholders listed in its prospectus to resell up to 13,342,953 shares of common stock, including 1,619,289 shares underlying warrants. ParkerVision will not receive proceeds from those resales. To the extent the warrants are exercised for cash, ParkerVision will receive up to $2,833,756 in gross proceeds, which it expects to use for general working capital, including litigation expenses.

At the September 25, 2026 annual meeting, shareholders elected Jeffrey L. Parker as a Class I director for a term expiring at the 2029 annual meeting and Anthony B. Bowers as a Class II director for the remaining term expiring at the 2027 annual meeting. Parker received 21,862,556 votes for and 837,457 withheld; Bowers received 22,063,764 votes for and 636,249 withheld. Shareholders also ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026.

ParkerVision, Inc. supplements its resale prospectus, which permits selling stockholders to resell up to 5,871,584 shares of common stock. ParkerVision states it will not receive proceeds from sales by the selling stockholders. The company also reported results from its September 25, 2026 annual meeting.

Shareholders elected Jeffrey L. Parker as a Class I director for a term expiring at the 2029 annual meeting and Anthony B. Bowers as a Class II director for the remaining term expiring at the 2027 annual meeting. They ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026. As of July 29, 2026, 148,226,874 shares of common stock were issued and outstanding and entitled to vote.

ParkerVision, Inc. (PRKR) supplements its prospectus covering the resale by selling stockholders of up to 16,809,295 shares of common stock. The company will not receive proceeds from stockholder resales; if the Aspire and Tailwinds warrants are exercised for cash, ParkerVision may receive up to $3,900,000 in gross proceeds, which it expects to use for general working capital and corporate purposes.

At the September 25, 2026 annual meeting, shareholders elected Jeffrey L. Parker to a Class I term expiring at the 2029 annual meeting and Anthony B. Bowers to the remaining Class II term expiring at the 2027 annual meeting. They also ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026.

ParkerVision, Inc. (PRKR) states that its prospectus permits selling stockholders to resell up to 18,014,164 shares of common stock. The shares include stock issuable upon conversion of two note tranches, 625,000 shares issued for consulting services, and 1,800,000 shares issuable under a consulting warrant with a $0.10 exercise price.

ParkerVision receives no proceeds from selling-stockholder resales; it could receive up to $180,000 in gross proceeds if the warrant is exercised for cash, for general working capital and corporate purposes. At its September 25, 2026 annual meeting, shareholders elected two directors and ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026.

ParkerVision, Inc. (PRKR) supplements a prospectus permitting selling stockholders to resell up to 17,189,660 shares of common stock with its September 25, 2026 annual-meeting results.

ParkerVision receives no proceeds from selling-stockholder resales. If the 2016 Warrant is exercised for cash, it would receive up to $700,000 in gross proceeds, and it may receive up to an additional $1,763,500 from common-stock sales or exercise of warrants issued to Aspire Capital under the PIPE Agreement. Proceeds from warrant exercises, if any, are expected to fund patent enforcement actions, working capital and general corporate purposes.

Shareholders elected Jeffrey L. Parker as Class I director, for a term expiring at the 2029 annual meeting, and Anthony B. Bowers for the remaining Class II term expiring at the 2027 annual meeting, with 21,862,556 and 22,063,764 votes for, respectively. They ratified Frazier & Deeter, LLC as independent registered public accounting firm for the year ending December 31, 2026, with 93,703,944 votes for.

ParkerVision, Inc.'s prospectus permits selling stockholders to resell up to 12,800,000 shares of common stock: 7,800,000 shares issuable upon conversion of convertible promissory notes or, at the company's option, for interest payments, plus 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from selling-stockholder resales; if the warrant is exercised for cash, it may receive up to $800,000 in gross proceeds, which it expects to use for patent enforcement actions and other working capital and general corporate purposes.

At the September 25, 2026 annual meeting, shareholders elected Jeffrey L. Parker as a Class I Director for a term expiring at the 2029 annual meeting and Anthony B. Bowers as a Class II Director for the remaining term expiring at the 2027 annual meeting. Shareholders ratified Frazier & Deeter, LLC as independent registered public accounting firm for the year ending December 31, 2026. ParkerVision had 148,226,874 common shares issued and outstanding and entitled to vote as of July 29, 2026.

ParkerVision, Inc. filed a prospectus supplement covering the resale of up to 9,387,500 shares of common stock by selling shareholders, including 2,843,750 already issued shares, 6,343,750 shares issuable upon conversion of convertible notes at $0.16 per share, and 200,000 shares issuable upon option exercises. The company will not receive proceeds from resales, and would receive up to $42,620 only if the options are exercised for cash.

The attached quarterly report for the period ended June 30, 2026 shows total assets of $3.7 million against total liabilities of $48.3 million, resulting in a shareholders’ deficit of $44.6 million. Net income was $148,000 for the quarter and a net loss of $1.4 million for the first six months, with $1.7 million of operating cash outflows and cash of $2.5 million remaining. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing reliance on uncertain patent-enforcement proceeds and the need for additional capital. Long-term obligations include a secured contingent payment obligation recorded at $39.0 million (undiscounted scenarios up to $146.6 million) and unsecured contingent payment obligations of $5.8 million, both tied to future patent-related recoveries, alongside $2.3 million in convertible notes and significant ongoing IP litigation.

ParkerVision, Inc. is updating a resale registration covering up to 16,638,353 shares of common stock issuable upon conversion of 2022 convertible notes at a fixed price of $0.13 per share.

For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue but recorded net income of $148,000, largely from a favorable $1.7 million change in the fair value of contingent payment obligations. For the first six months of 2026, it posted a net loss of $1.4 million and used $1.7 million of cash in operations.

Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, against total liabilities of $48.3 million and a shareholders’ deficit of $44.6 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next year, given dependence on uncertain patent-enforcement proceeds, significant secured contingent payment obligations with fair value of $39.0 million (underlying note balance roughly $71.5 million), $5.8 million of unsecured contingent obligations, and $2.3 million of convertible notes, including $1.1 million maturing within 12 months.

ParkerVision, Inc. registered for resale up to 1,578,946 shares of common stock held by a selling stockholder, including 526,315 shares issuable upon warrant exercise. The company will not receive proceeds from share resales and would receive up to $526,315 only if the warrants are exercised for cash, for general working capital and litigation expenses.

For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue and net income of $148,000, with a six‑month net loss of $1.4 million. Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, while total liabilities were $48.3 million against $3.7 million of assets, resulting in a shareholders’ deficit of $44.6 million.

The company records large secured contingent payment obligations at fair value of $39.0 million and unsecured contingent payment obligations of $5.8 million, tied to future patent‑related proceeds. Management discloses substantial doubt about its ability to continue as a going concern over the next year, citing dependence on uncertain litigation and licensing outcomes, behavior of convertible note holders, and access to additional financing.

ParkerVision, Inc. registered for resale up to 13,342,953 shares of common stock, including shares issued in prior securities purchase agreements, shares underlying 1,619,289 warrants, and shares issued for services. Selling stockholders receive sale proceeds; ParkerVision would receive up to $2,833,756 only if the warrants are exercised for cash, which it plans to use for working capital and litigation expenses.

For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue and net income of $148,000, driven mainly by a favorable $1.7 million change in fair value of contingent payment obligations, while the six‑month period showed a net loss of $1.4 million. Cash was $2.5 million with working capital of $0.8 million and an accumulated deficit of $457.0 million, alongside large fair‑value liabilities for secured ($39.0 million) and unsecured ($5.8 million) contingent payment obligations. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year.

ParkerVision, Inc. is filing a prospectus supplement covering resale of up to 5,871,584 shares of common stock by selling stockholders; the company will not receive proceeds from these sales. The supplement incorporates the June 30, 2026 Form 10-Q.

ParkerVision licenses wireless RF technologies and pursues patent-enforcement litigation as its primary business model. For the first half of 2026 it reported a net loss of $1.4 million and no licensing revenue, with cash used in operations of $1.7 million. Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, against a shareholders’ deficit of $44.6 million.

The balance sheet is dominated by fair-valued contingent payment obligations tied to litigation proceeds, including $39.0 million secured and $5.8 million unsecured obligations. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year absent successful licensing, favorable note-holder behavior, cost control, and/or new financing.

ParkerVision, Inc. registered for resale by selling stockholders up to 16,809,295 shares of common stock, including shares issuable upon conversion of convertible notes and exercise of warrants. The company will not receive proceeds from these resales, but could receive up to $3.9 million in gross proceeds if Aspire and Tailwinds warrants are exercised for cash, to be used for general working capital and corporate purposes.

For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000 and a six‑month net loss of $1.4 million, with $2.5 million in cash and cash equivalents and an accumulated deficit of $457.0 million. Fair value of secured and unsecured contingent payment obligations totaled $44.8 million, and management disclosed substantial doubt about the ability to continue as a going concern given limited working capital, upcoming convertible debt maturities, and dependence on uncertain patent‑enforcement proceeds.

ParkerVision, Inc. has registered for resale by existing holders up to 18,014,164 shares of common stock, including shares issuable upon conversion of prior convertible notes, for services and upon exercise of a consulting warrant. The company will not receive proceeds from stockholder resales, but could receive up to $180,000 in cash if the consulting warrant is exercised, which would be used for general working capital and corporate purposes.

For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000, but a six‑month net loss of $1.4 million and operating cash outflows of $1.7 million. Cash and cash equivalents were $2.5 million, with total assets of $3.7 million versus total liabilities of $48.3 million, resulting in a shareholders’ deficit of $44.6 million. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year, given recurring losses, limited liquidity, and $2.3 million of convertible notes, of which $1.1 million is current, plus large secured and unsecured contingent payment obligations tied to future patent-enforcement proceeds.

ParkerVision, Inc. filed a prospectus supplement covering the resale by existing holders of up to 17,189,660 shares of common stock previously registered under multiple shelf and Form S-1 registration statements. The company will not receive proceeds from these resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from share and warrant sales under the Aspire Capital agreement, which it expects to use for patent enforcement, working capital, and general corporate purposes.

For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000, driven largely by a $1.7 million gain from remeasuring contingent payment obligations, while posting a six‑month net loss of $1.4 million. Cash and cash equivalents were $2.5 million, working capital was about $0.8 million, and the company reported a shareholders’ deficit of $44.6 million with an accumulated deficit of $457.0 million. Management discloses that substantial doubt exists about its ability to continue as a going concern absent successful patent licensing outcomes, favorable behavior from convertible note holders, and/or new debt or equity financing.

ParkerVision, Inc. filed a prospectus supplement updating a resale registration that permits selling stockholders to resell up to 12,800,000 shares of common stock, including shares issuable from convertible notes and a five-year warrant. The company is not selling shares and will only receive cash if the warrant is exercised, up to $800,000, which it plans to use for patent enforcement, working capital, and general corporate purposes.

Attached financials for the quarter ended June 30, 2026 show cash of $2.5 million, working capital of about $0.8 million, a six‑month net loss of $1.4 million, and an accumulated deficit of $457.0 million. Large fair‑valued obligations include a secured contingent payment obligation of $39.0 million and unsecured contingent obligations of $5.8 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next year absent successful licensing outcomes and/or new financing.

ParkerVision, Inc. files a Prospectus Supplement registering 9,387,500 shares of Common Stock for resale by the selling shareholders. The registered shares consist of 2,843,750 issued shares, 6,343,750 shares issuable upon conversion of Convertible Notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of Options. The company will not receive proceeds from resale by the selling shareholders; if the Options are exercised for cash, the company could receive up to $42,620 in gross proceeds. This supplement updates the Prospectus with information furnished on May 21, 2026.

ParkerVision, Inc. registers 16,638,353 shares of Common Stock for resale by selling shareholders.

The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share. This Prospectus Supplement (dated May 21, 2026) supplements the Prospectus dated August 22, 2022 and attaches a Form 8-K furnished on May 21, 2026. The resale registration covers shares held by the selling shareholders named in the Prospectus.

ParkerVision, Inc. files a Prospectus Supplement registering 1,578,946 shares of Common Stock for resale by a selling stockholder.

The registration covers an aggregate of 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from resales; if the Warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K disclosing that director Lewis Titterton resigned effective May 15, 2026 and that Anthony Bowers was appointed to the Board and its Audit and Compensation Committees on May 19, 2026.

ParkerVision, Inc. is updating a resale prospectus to register 13,342,953 shares of Common Stock for resale by selling stockholders under the Prospectus Supplement dated May 21, 2026. The shares consist of several issuances, including 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares plus 1,619,289 shares underlying warrants, and 530,000 shares issued for services.

The company states it will not receive proceeds from resale of the registered shares; however, if the Warrants are exercised for cash, the company would receive up to $2,833,756, which it expects to use for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K that discloses a director resignation on May 15, 2026 and the appointment of a new director on May 19, 2026. The company’s common stock trades on the OTCQB under the symbol PRKR.

ParkerVision, Inc. registers 5,871,584 shares of Common Stock for resale by selling stockholders under a Prospectus Supplement dated May 21, 2026. The company will not receive proceeds from these resales. The supplement attaches a Form 8-K filed May 21, 2026, which furnishes a press release.

The Form 8-K discloses a director resignation and board appointment: May 15, 2026 resignation of Lewis Titterton (retirement) and appointment of Anthony Bowers on May 19, 2026, who joins the Audit and Compensation Committees and will receive standard non-employee director compensation and the company’s standard indemnification agreement.

ParkerVision, Inc. files a prospectus supplement registering 16,809,295 shares of Common Stock for resale by selling stockholders under its April 28, 2020 prospectus. The supplement notes the company will not receive proceeds from those resales; cash proceeds up to $3,900,000 may result if certain warrants are exercised.

The filing also furnishes a Form 8-K reporting the resignation of director Lewis Titterton due to retirement and the Board's appointment of Anthony Bowers to fill the vacancy and to serve on the Audit and Compensation Committees.

ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders.

The shares comprise convertible-note conversions, consulting issuances and a warrant; the company will not receive proceeds from resales, except it would receive up to $180,000 if the Park Consulting Warrant is exercised for cash. The supplement incorporates an attached Form 8-K describing a director resignation and appointment.

ParkerVision, Inc. filed a prospectus supplement registering 17,189,660 shares of Common Stock for resale by selling stockholders pursuant to prior registration statements.

The supplement confirms the company will not receive proceeds from resales, although it may receive proceeds from certain warrant exercises (up to $700,000 and up to $1,763,500 related to Aspire Capital arrangements). The supplement also furnishes a Form 8-K reporting a director resignation and appointment.

ParkerVision, Inc. files a Prospectus Supplement registering 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from resales by selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 in gross proceeds to fund patent enforcement actions and for working capital. This supplement incorporates an attached Form 8-K that discloses a director resignation and a new director appointment.

ParkerVision, Inc. registers 9,387,500 shares of Common Stock for resale by selling shareholders as set forth in the prospectus supplement dated May 7, 2026.

The prospectus supplement states the company will not receive proceeds from resales by the selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620 in gross proceeds to be used for general working capital purposes. As of May 1, 2026, 147,767,649 shares of common stock were outstanding.

ParkerVision, Inc. registers the resale of up to 16,638,353 shares of Common Stock issuable upon conversion of convertible promissory notes with a fixed conversion price of $0.13 per share. This supplement attaches the company's Form 10-Q filed May 7, 2026.

The 10-Q shows cash and cash equivalents of $3.4 million, an accumulated deficit of $457.2 million, and a secured contingent payment obligation measured at fair value of $40.1 million. Shares outstanding were 147,767,649 as of May 1, 2026. The 10-Q also discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months.

ParkerVision, Inc. files a prospectus supplement registering 1,578,946 shares of common stock for resale by a selling stockholder. The registration covers 1,052,631 shares and 526,315 shares underlying warrants issued under a December 14, 2021 agreement. The company will not receive proceeds from the resale; however, if the 526,315 Warrants are exercised for cash, the company would receive up to $526,315 in gross proceeds to be used for general working capital, including litigation expenses. Shares outstanding were 147,767,649 as of May 1, 2026. This supplement updates the prospectus with the company’s Form 10-Q for the quarter ended March 31, 2026.

ParkerVision, Inc. filed a Prospectus Supplement dated May 7, 2026 registering the resale of 13,342,953 shares of Common Stock under a prior prospectus. The supplement states the company will not receive proceeds from sales by the selling stockholders; however, if underlying warrants are exercised for cash, the company would receive up to $2,833,756 in gross proceeds.

The supplement attaches the company’s Form 10-Q for the quarter ended March 31, 2026, which shows cash of $3.4 million, a net loss for the quarter of $1.553 million, and total secured contingent payment obligations measured at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The filing reiterates substantial litigation-driven operations, contingent payment obligations tied to patent proceeds, and management’s statement of substantial doubt about going concern for the next year.

ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of common stock for resale by selling stockholders. The supplement attaches ParkerVision’s Form 10-Q for the quarter ended March 31, 2026 and states the company will not receive proceeds from these resales.

The Form 10-Q shows $3.4 million in cash, a net loss of $1.553 million for the three months ended March 31, 2026, secured contingent payment obligations of $40.144 million, and 147,767,649 shares outstanding as of May 1, 2026. The filing discloses substantial doubt about the company’s ability to continue as a going concern for one year.